Pancreatic cancer is one of the most dangerous forms of cancer in the world. Doctors and scientists have struggled for many years to find effective treatments for it.
Many patients are diagnosed at a late stage because the disease often develops silently and does not cause clear symptoms in its early stages. By the time it is discovered, the cancer has often already spread or become difficult to treat.
Around the world, pancreatic cancer has a very high death rate. In Singapore, for example, it is only the ninth most common cancer, yet it is the fourth leading cause of cancer-related deaths. This shows how serious the disease can be. Even when patients receive treatment, the benefits are often limited.
For most people with pancreatic cancer, chemotherapy remains the main treatment. Chemotherapy drugs are designed to kill rapidly growing cancer cells. However, pancreatic tumors often respond poorly to these drugs. Some tumors may shrink for a short time, but many quickly become resistant, meaning the treatment stops working.
Because of this problem, scientists have been trying to understand why pancreatic cancer cells sometimes respond to chemotherapy and sometimes resist it.
A team of researchers from Duke-NUS Medical School has now discovered an important clue. They found a molecular “switch” inside pancreatic cancer cells that appears to control whether tumors respond to chemotherapy or resist it. Their findings were published in the Journal of Clinical Investigation.
To understand the importance of this discovery, it helps to know that pancreatic cancer cells can exist in different states. Over the past decade, researchers have identified two major subtypes of pancreatic cancer. These are known as the classical subtype and the basal subtype.
The classical subtype tends to grow in a more organized way. Tumor cells in this state look more similar to normal cells and are often easier to treat. Patients with this subtype are more likely to respond to chemotherapy.
The basal subtype is very different. Tumor cells in this state are more disorganized and aggressive. They grow faster and are much harder to treat. Patients with basal-type tumors usually have poorer outcomes.
One surprising fact about pancreatic cancer is that tumor cells can switch between these two states. A tumor that starts in the classical state can change into the basal state over time. When this happens, the cancer becomes more resistant to treatment. Scientists call this ability “cancer cell plasticity,” meaning the cells are flexible and can change their behavior.
The research team wanted to understand what causes this switch.
They focused on a gene called GATA6. Genes are pieces of DNA that give cells instructions for making proteins. The researchers discovered that GATA6 plays a key role in keeping pancreatic cancer cells in the classical state.
When levels of GATA6 are high, tumor cells remain more structured and organized. In this state, chemotherapy drugs are more likely to work. But when GATA6 levels fall, the cancer cells become more chaotic and aggressive. This shift pushes the tumor toward the basal subtype, which is much more resistant to treatment.
The scientists then looked deeper into the molecular signals that control GATA6.
They found that a well-known cancer gene called KRAS plays an important role. Mutations in KRAS are found in almost all pancreatic cancers. These mutations send constant signals that tell cancer cells to grow and divide.
KRAS passes its signals through another molecule called ERK. This pathway acts like a chain of messages moving through the cell. When the KRAS–ERK pathway becomes very active, it protects another protein that interferes with the production of GATA6.
As a result, GATA6 levels drop. When this happens, cancer cells lose their organized structure and shift into the more aggressive basal state.
The research team tested whether this process could be reversed. They used genetic tools and drugs to block the KRAS–ERK pathway inside cancer cells.
When this pathway was blocked, the suppression of GATA6 was removed. GATA6 levels increased again. As a result, the cancer cells moved back toward the classical state and became more sensitive to chemotherapy.
This discovery suggests that certain targeted drugs could potentially “reset” pancreatic cancer cells, making them easier to treat.
The researchers also tested combination treatments. They found that when drugs that block the KRAS–ERK pathway were used together with chemotherapy, the anti-cancer effects were stronger than using either treatment alone.
However, this improvement occurred mainly in tumors where GATA6 was present. This means that GATA6 could also serve as a marker to help doctors identify which patients are most likely to benefit from this treatment strategy.
The findings help explain why some pancreatic cancer patients respond better to chemotherapy than others. Tumors with higher GATA6 levels appear to remain in the more treatable classical state, while tumors with low GATA6 are more likely to resist treatment.
The discovery may also have implications beyond pancreatic cancer. KRAS mutations are common in several other types of cancer, including lung and colorectal cancers. These cancers also show changes in cell behavior that affect treatment response.
By understanding how cancer cells switch between different states, scientists may be able to design better treatments that prevent tumors from becoming resistant.
When reviewing this study, it becomes clear that cancer resistance is not always caused by permanent genetic changes. Sometimes it results from flexible biological programs inside cells that can shift depending on signals within the tumor environment.
The discovery of this molecular switch offers hope that scientists may be able to push cancer cells back into a more treatable state. Instead of only trying to kill cancer cells directly, future therapies might focus on changing the internal signals that control tumor behavior.
Although more research and clinical trials will be needed, the study provides an important step toward improving treatments for one of the most difficult cancers to manage.
If these findings continue to hold true in patients, combining targeted drugs with chemotherapy could eventually give doctors a powerful new strategy to fight pancreatic cancer and possibly other KRAS-driven cancers as well.
If you care about cancer, please read studies that artificial sweeteners are linked to higher cancer risk, and how drinking milk affects risks of heart disease and cancer.
For more health information, please see recent studies about the best time to take vitamins to prevent heart disease, and results showing vitamin D supplements strongly reduces cancer death.
Copyright © 2026 Knowridge Science Report. All rights reserved.
